麻疹・おたふくかぜ・風疹ワクチンの世界市場：市場規模・シェア・動向分析 (種類別・対象人口層別・流通チャネル別・地域別)、セグメント別予測 (2025年～2030年)

麻疹・おたふくかぜ・風疹ワクチン市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の麻疹・おたふくかぜ・風疹ワクチン市場規模は、2025年から2030年にかけて8.47%のCAGRを記録し、2030年までに29億5,000万米ドルに達する見込みです。

この成長は、政府支援と公衆衛生キャンペーンの増加によるものです。重要な転機となったのは、2025年4月、テキサス州ではしかの集団感染が急増する中、長年ワクチンに懐疑的であったロバート・F・ケネディ・ジュニア米国保健長官がMMRワクチンを公的に承認したことです。テキサス州で2人目の麻疹関連死が発生した後、ケネディ長官は公の場でMMRワクチンの接種を支持し、撤回しました。ケネディの発言は、それまでの支持層の反発を招いたもの、世間の認識を変え、MMRワクチン接種の重要性を強化する上で重要な役割を果たしました。この出来事は、ワクチン接種キャンペーンを後押しし、躊躇している人々のコンプライアンスを向上させるきっかけとなりました。特に反ワクチン感情の高まりに直面している地域では、予防接種率を高め、将来の集団感染リスクを最小限に抑えるための取り組みを強化することができます。

製品承認もMMRワクチン市場の主要な成長要因です。2022年6月、GSKは米国食品医薬品局（FDA）から、生後12ヵ月以上の麻疹・おたふくかぜ・風疹に対する積極的予防接種用ワクチンとしてPriorixが承認されたと発表しました。Priorixはすでにカナダ、オーストラリア、欧州を含む100カ国以上で認可されており、全世界で8億回接種されており、その信頼性と広く使用されていることが実証されています。FDAの承認により、米国の医療従事者はメルク社のM-M-R IIに代わる選択肢を得ることができ、サプライチェーンの強靭性が強化され、世界のアウトブレイクの中で高まる需要に応えることができるようになりました。選択肢が増えることで競争も促進され、コスト削減や入手のしやすさが向上する可能性もあります。このような規制当局の承認は、新しいワクチンの安全性と有効性を証明するだけでなく、医療専門家と躊躇している個人の両方への採用を促進することにより、市場全体を拡大します。

政府のイニシアチブは、MMRワクチン市場の成長を促進する上で引き続き中心的な役割を果たしています。2025年2月、ニューメキシコ州保健局は、麻疹患者の憂慮すべき増加に対応して専用のオンラインリソースを立ち上げました。このイニシアチブは、認知度の向上、地域の発生状況の特定、適時のワクチン接種の重要性の啓蒙に重点を置いたものでした。これは、州や国の政府がデジタル・プラットフォームを活用することで、市民の関心を高め、誤った情報に対処し、予防接種の後方支援を行うという、より広範な動向を象徴するものです。政府主導の啓発キャンペーン、就学前ワクチン接種の義務化、予防接種プログラムへの資金増額は、アウトブレイクのリスクを軽減し、地域全体の予防を確保する上で効果的であることが証明されつつあります。このような努力は、特にCOVID-19パンデミック時の挫折を経て、麻疹排除目標の達成に向けた世界の政策的コミットメントを反映しています。高いワクチン接種率を維持し、公衆衛生の取り組みを成功させるためには、政府の協調的な行動が依然として不可欠です。

アジア太平洋地域では、MMRワクチンの入手可能性を拡大するために、現地製造業者と官民協力が重要な役割を果たしています。2023年11月、インディアン・イミュノロジカルズ社（IIL）は、ベトナムのポリバック研究所と共同で開発した麻疹・風疹混合ワクチンであるマベラワクチンを発売しました。この発売は、ヒト生物学研究所の設立25周年と同時に行われ、国民に安価なワクチンを提供するインドの取り組みにおいて重要な節目となりました。Mabellaワクチンは、年間数百万人の子どもたちを対象とするインドの万国予防接種プログラム（UIP）を支援するものです。国産で費用対効果の高い代替ワクチンを提供することで、今回の発売は、特に十分なサービスを受けていない地域におけるワクチン接種率を強化する可能性があります。さらに、このような協力関係は、地域におけるワクチンの自給自足と技術革新の重要性を示しています。アジア太平洋地域でより多くの国々が独自のワクチンを開発し、ライセンス供与を受けるようになれば、地域市場は急成長し、輸入製剤への依存度が低下し、医療インフラが強化されることになります。

局地的な流行に対応するための予防接種プログラムも、市場拡大に大きく寄与しています。例えば、スリランカ保健省は2024年11月、麻疹患者の増加を受け、特定の地区を対象とした特別予防接種キャンペーンを開始しました。この1週間にわたるプログラムは、予防接種率が低下している高リスク地域に焦点を当て、迅速な戸別ワクチン配備によって感染拡大を食い止めることを目的としていました。このような重点的な介入は、機敏で的を絞った戦略によって、免疫力のギャップを迅速に埋め、病気の再発を防ぐことができることを示しています。このような国の取り組みは、WHOやユニセフのような世界の保健機関から支援を受けることが多く、その影響力をさらに増幅させています。低・中所得国では、定期的なワクチン接種システムがインフラや資金面での問題に直面する可能性があるため、こうした的を絞った取り組みは極めて重要です。これらのキャンペーンは、対応力のある公衆衛生政策の重要性を浮き彫りにし、たとえ短期間のキャンペーンであっても、市場の需要を喚起し、現地のワクチン流通網を支援し、世界の疾病撲滅目標に貢献できることを実証しています。

麻疹・おたふくかぜ・風疹ワクチン市場：分析概要

• 種類別では、4価ワクチンが2024年に57.37%の収益シェアを占め、2025年から2030年にかけて大きな成長が見込まれます。この急成長の主な要因は、1回の投与で複数の疾病に対する予防効果を発揮する包括的な予防接種ソリューションに対する需要の高まりです。
• 対象人口層別では、2024年には乳幼児（9ヵ月～12ヵ月）分野が67.96%の最大市場シェアを占め、2025年から2030年にかけて大きな成長が見込まれます。
• 流通チャネル別では、2024年には、ワクチンセンターと公衆衛生クリニック部門が市場をリードし、41.65%の最大市場シェアを獲得しました。地域保健センターや政府運営の予防接種クリニックを含むこれらの公的医療施設は、特に国民のほとんどが公的医療を主体としている地域において、MMRワクチンの主要な供給者としての役割を担っています。予防接種実施における保健所の極めて重要な役割は、インドの普遍的予防接種プログラム（UIP）のような政府出資のイニシアチブによってさらに強化されています。
• 北米の麻疹・おたふくかぜ・風疹ワクチン市場が最大の市場シェアを占めていますが、これは同地域全域における流行の抑制とワクチン接種率の向上を目的とした政府の強力な取り組みと公衆衛生イニシアチブの拡大が後押ししています。

目次

第1章 分析方法・範囲

第2章 エグゼクティブサマリー

第3章 麻疹・おたふくかぜ・風疹ワクチン市場：変動要因・傾向・範囲

• 市場の区分と範囲
• 市場連関の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場動向と展望
• 市場力学
  • 強化された政府の予防接種プログラム
  • 感染再拡大と疾病負担の増大
  • 啓発・教育キャンペーン
• 市場抑制要因分析
  • ワクチン接種への躊躇と誤情報
• 種類別の分析ツール
  • ポーターのファイブフォース分析
  • PESTEL分析
• 市場機会分析
• 市場の新興戦略

第4章 麻疹・おたふくかぜ・風疹ワクチン市場：種類別の推定・動向分析

• 麻疹・おたふくかぜ・風疹ワクチン市場：種類別の変動分析
• タイプ別
• 一価
  • 一価ワクチン市場（2018～2030年）
• 三価（混合MMR）
  • 三価（複合MMR）ワクチン市場（2018～2030年）
• 四価
  • 四価ワクチン市場（2018～2030年）

第5章 麻疹・おたふくかぜ・風疹ワクチン市場：対象人口層別の推定・動向分析

• 麻疹・おたふくかぜ・風疹ワクチン市場：対象人口層別の変動分析
• 対象人口別
• 乳幼児（9ヶ月～12歳）
  • 乳幼児（9ヶ月～12歳）市場（2018～2030年）
• 成人
  • 成人市場（2018～2030年）

第6章 麻疹・おたふくかぜ・風疹ワクチン市場：流通チャネル別の推定・動向分析

• 麻疹・おたふくかぜ・風疹ワクチン市場：流通チャネル別の変動分析
• 流通チャネル別
• 病院・医療機関
  • 病院・医療機関市場（2018～2030年）
• ワクチンセンター・公衆衛生クリニック
  • ワクチンセンター・公衆衛生クリニック市場（2018～2030年）
• 小児科・開業医
  • 小児科・開業医市場（2018～2030年）

第7章 麻疹・おたふくかぜ・風疹ワクチン市場：地域別の推定・動向分析

• 麻疹・おたふくかぜ・風疹ワクチン：地域別市場シェア（2024年・2030年）
• 市場シェア分析：地域別（2024年・2030年）
• 市場ダッシュボード：地域別
• 世界市場のスナップショット：地域別
• 市場規模の予測と動向分析（2018～2030年）
• 北米
  • 北米の麻疹・おたふくかぜ・風疹ワクチン市場（2018～2030年）
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 欧州の麻疹・おたふくかぜ・風疹ワクチン市場（2018～2030年）
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • アジア太平洋の麻疹・おたふくかぜ・風疹ワクチン市場（2018～2030年）
  • 日本
  • 中国
  • インド
  • オーストラリア
  • タイ
  • 韓国
• ラテンアメリカ
  • ラテンアメリカの麻疹・おたふくかぜ・風疹ワクチン市場（2018～2030年）
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 中東・アフリカの麻疹・おたふくかぜ・風疹ワクチン市場（2018～2030年）
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 最近の動向と影響分析：主要市場参入企業別
• 企業分類
• 戦略マッピング
• 企業市場シェア分析（2024年）
• 企業プロファイル
  • Merck &Co., Inc.
  • GSK
  • Serum Institute of India Pvt. Ltd.
  • Sanofi
  • Shanghai Institute of Biological Products
  • Beijing Institute of Biological Products
  • Biological E Ltd.
  • Sinovac

List of Table

• Table 1 List of abbreviations
• Table 2 Global Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 3 Global Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
• Table 4 Global Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 5 Global Measles, Mumps, Rubella Vaccines Market, by Region, 2018 - 2030 (USD Million)
• Table 6 North America Measles, Mumps, Rubella Vaccines Market, by Country, 2018 - 2030 (USD Million)
• Table 7 North America Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 8 North America Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
• Table 9 North America Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 10 U.S. Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 11 U.S. Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
• Table 12 U.S. Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 13 Canada Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 14 Canada Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
• Table 15 Canada Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 16 Europe Measles, Mumps, Rubella Vaccines Market, by Country, 2018 - 2030 (USD Million)
• Table 17 Europe Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 18 Europe America Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
• Table 19 Europe America Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 20 UK Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 21 UK Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
• Table 22 UK Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 23 Germany Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 24 Germany Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
• Table 25 Germany Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 26 France Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 27 France Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
• Table 28 France Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 29 Italy Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 30 Italy Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
• Table 31 Italy Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 32 Spain Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 33 Spain Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
• Table 34 Spain Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 35 Denmark Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 36 Denmark Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
• Table 37 Denmark Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 38 Sweden Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 39 Sweden Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
• Table 40 Sweden Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 41 Norway Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 42 Norway Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
• Table 43 Norway Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 44 Asia Pacific Measles, Mumps, Rubella Vaccines Market, by Country, 2018 - 2030 (USD Million)
• Table 45 Asia Pacific Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 46 Asia Pacific Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
• Table 47 Asia Pacific Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 48 Japan Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 49 Japan Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
• Table 50 Japan Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 51 China Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 52 China Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
• Table 53 China Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 54 India Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 55 India Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
• Table 56 India Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 57 Australia Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 58 Australia Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
• Table 59 Australia Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 60 Thailand Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 61 Thailand Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
• Table 62 Thailand Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 63 South Korea Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 64 South Korea Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
• Table 65 South Korea Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 66 Latin America Measles, Mumps, Rubella Vaccines Market, by Country, 2018 - 2030 (USD Million)
• Table 67 Latin America Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 68 Latin America Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
• Table 69 Latin America Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 70 Brazil Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 71 Brazil Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
• Table 72 Brazil Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 73 Mexico Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 74 Mexico Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
• Table 75 Mexico Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 76 Argentina Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 77 Argentina Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
• Table 78 Argentina Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 79 Middle East & Africa Measles, Mumps, Rubella Vaccines Market, by Country, 2018 - 2030 (USD Million)
• Table 80 Middle East & Africa Measles, Mumps, Rubella Vaccines Market, by type, 2018 - 2030 (USD Million)
• Table 81 Middle East & Africa Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
• Table 82 Middle East & Africa Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 83 South Africa Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 84 South Africa Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
• Table 85 South Africa Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 86 Saudi Arabia Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 87 Saudi Arabia Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
• Table 88 Saudi Arabia Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 89 UAE Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 90 UAE Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
• Table 91 UAE Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 92 Kuwait Measles, Mumps, Rubella Vaccines Market, by Type, 2018 - 2030 (USD Million)
• Table 93 Kuwait Measles, Mumps, Rubella Vaccines Market, by Targeted Population, 2018 - 2030 (USD Million)
• Table 94 Kuwait Measles, Mumps, Rubella Vaccines Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information procurement
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value chain-based sizing & forecasting
• Fig. 6 Market formulation & validation
• Fig. 7 Measles, Mumps, Rubella Vaccines Market segmentation
• Fig. 8 Market snapshot, 2024
• Fig. 9 Market trends & outlook
• Fig. 10 Market driver relevance analysis (current & future impact)
• Fig. 11 Market restraint relevance analysis (current & future impact)
• Fig. 12 SWOT analysis, by factor (political & legal, economic, and technological)
• Fig. 13 Porter's five forces analysis
• Fig. 14 Measles, mumps, rubella vaccines market: Type movement analysis
• Fig. 15 Measles, mumps, rubella vaccines market: Type outlook and key takeaways
• Fig. 16 Monovalent market estimates and forecast, 2018 - 2030
• Fig. 17 Trivalent (combined MMR) market estimates and forecast, 2018 - 2030
• Fig. 18 Tetravalent market estimates and forecast, 2018 - 2030
• Fig. 19 Measles, mumps, rubella vaccines market: Targeted Population movement analysis
• Fig. 20 Measles, mumps, rubella vaccines market: Targeted Population outlook and key takeaways
• Fig. 21 Infants and children (9 months to 12) market estimates and forecast, 2018 - 2030
• Fig. 22 Adults (catch-up vaccination) market estimates and forecast, 2018 - 2030
• Fig. 23 Measles, mumps, rubella vaccines market: Distribution channel movement analysis
• Fig. 24 Measles, mumps, rubella vaccines market: Distribution channel outlook and key takeaways
• Fig. 25 Hospitals market estimates and forecast, 2018 - 2030
• Fig. 26 Hospitals and healthcare institutions market estimates and forecast, 2018 - 2030
• Fig. 27 Vaccine centers and public health clinics market estimates and forecast, 2018 - 2030
• Fig. 28 Pediatric and private healthcare clinics market estimates and forecast, 2018 - 2030
• Fig. 29 Regional outlook, 2024 & 2030
• Fig. 30 Global Measles, Mumps, Rubella Vaccines Market: Region movement analysis
• Fig. 31 North America Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 32 U.S. Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 33 Canada Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 34 Mexico Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 35 Europe Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 36 Germany Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 37 UK Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 38 France Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 39 Italy Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 40 Spain Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 41 Denmark Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 42 Sweden Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 43 Norway Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 44 Asia Pacific Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 45 Japan Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 46 China Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 47 India Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 48 Australia Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 49 South Korea Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 50 Thailand Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 51 Latin America Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 52 Brazil Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 53 Argentina Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 54 Middle East and Africa Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 55 South Africa Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 56 Saudi Arabia Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 57 UAE Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
• Fig. 58 Kuwait Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)

Measles, Mumps, Rubella Vaccine Market Growth & Trends:

The global measles, mumps, rubella vaccine market size is expected to reach USD 2.95 billion by 2030, registering a CAGR of 8.47% from 2025 to 2030, according to a new report by Grand View Research, Inc. This growth is due to increasing government support and public health campaigns. A key turning point was in April 2025, when the U.S. Health Secretary Robert F. Kennedy Jr., a long-time vaccine skeptic, publicly endorsed the MMR vaccine amidst a surge in measles outbreaks in Texas. His public reversal and endorsement came after the second measles-related death in the state, drawing significant media attention and spurring nationwide discussion. Although it stirred backlash from segments of his prior supporter base, Kennedy's statement played a vital role in shifting public perception and reinforcing the importance of MMR vaccination. This event served as a catalyst for boosting vaccination campaigns and improving compliance among hesitant populations. High-profile endorsements can create powerful ripple effects across communities, strengthening efforts to increase immunization coverage and minimize the risk of future outbreaks, especially in areas facing rising anti-vaccine sentiment.

Product approval is another major growth driver in the MMR vaccine market. In June 2022, GSK announced that the U.S. Food and Drug Administration (FDA) approved its Priorix vaccine for active immunization against measles, mumps, and rubella in individuals aged 12 months and older. Already licensed in over 100 countries, including Canada, Australia, and across Europe, Priorix has distributed over 800 million doses globally, demonstrating its reliability and widespread use. Its FDA approval provided U.S. healthcare providers with an alternative to Merck's M-M-R II, enhancing supply chain resilience and meeting rising demand amid global outbreaks. The availability of more options also fosters competition, potentially reducing costs and improving accessibility. Regulatory approvals such as this not only validate the safety and efficacy of new vaccines but also expand the overall market by encouraging adoption among both healthcare professionals and hesitant individuals.

Government initiatives continue to play a central role in driving the MMR vaccine market growth. In February 2025, the New Mexico Department of Health launched a dedicated online resource in response to an alarming rise in measles cases. This initiative focused on raising awareness, identifying local outbreaks, and educating the public about the importance of timely vaccination. It represents a broader trend in which state and national governments are leveraging digital platforms to enhance public engagement, address misinformation, and support immunization logistics. Government-led awareness campaigns, school-entry vaccine requirements, and increased funding for immunization programs are proving effective in mitigating outbreak risks and ensuring community-wide protection. Such efforts reflect a global policy commitment to achieve measles elimination targets, especially after setbacks during the COVID-19 pandemic. Coordinated government action remains critical in maintaining high vaccination rates and ensuring the success of public health efforts.

In the Asia Pacific region, local manufacturers and public-private collaborations are playing a vital role in expanding MMR vaccine accessibility. In November 2023, Indian Immunologicals Limited (IIL) launched the Mabella vaccine-a measles and rubella combination vaccine developed in partnership with the Polyvac Institute of Vietnam. This launch coincided with the 25th anniversary of the Human Biologicals Institute and marked a significant milestone in India's efforts to provide affordable vaccines to its population. The Mabella vaccine supports India's Universal Immunization Programme (UIP), which targets millions of children annually. By offering a domestically produced, cost-effective alternative, this launch has the potential to strengthen vaccination coverage, especially in underserved regions. Moreover, such collaborations signify the importance of regional vaccine self-sufficiency and innovation. As more countries in Asia Pacific develop and license their own vaccines, the regional market is set to grow rapidly, reducing dependency on imported formulations and boosting health infrastructure.

Targeted immunization programs in response to localized outbreaks also contribute significantly to market expansion. For example, in November 2024, Sri Lanka's Ministry of Health initiated a special vaccination campaign targeting specific districts following a rise in measles cases. This week-long program focused on high-risk areas where immunization coverage had declined and aimed to contain the spread through rapid, door-to-door vaccine deployment. These focused interventions showcase how agile, targeted strategies can rapidly close immunity gaps and prevent disease resurgence. Such national initiatives often receive support from global health organizations like the WHO and UNICEF, further amplifying their impact. In low- and middle-income countries, where routine vaccination systems may face infrastructural or funding challenges, these targeted drives are crucial. They highlight the importance of responsive public health policies and demonstrate how even short-term campaigns can fuel market demand, support local vaccine distribution networks, and contribute to global disease elimination goals.

Measles, Mumps, Rubella Vaccine Market Report Highlights:

• Based on type, the tetravalent segment accounted for the largest revenue share of 57.37% in 2024 and is anticipated to witness significant growth from 2025 to 2030. This surge is primarily fueled by the growing demand for comprehensive immunization solutions that provide protection against multiple diseases in a single dose.
• Based on the targeted population, the infants and children (9 months to 12) segment dominated with the largest market share of 67.96% in 2024, and is anticipated to witness significant growth from 2025 to 2030, driven by increasing global immunization efforts and heightened awareness of vaccine-preventable diseases.
• In 2024, the vaccine centers and public health clinics segment led the distribution channel category, capturing the largest market share at 41.65%. These public health facilities-including community health centers and government-run vaccination clinics-serve as primary providers of MMR vaccines, particularly in areas where public healthcare is the mainstay for most of the population. Their pivotal role in immunization delivery is further bolstered by government-funded initiatives, such as India's Universal Immunization Programme (UIP), which has played a critical part in broadening access to vaccines across the country.
• The North American measles, mumps, and rubella vaccine market holds the largest market share, fueled by strong government efforts and expanded public health initiatives aimed at controlling outbreaks and increasing vaccination coverage across the region.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Targeted Population
  • 1.2.3. Distribution Channel
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Targeted Population outlook
  • 2.2.3. Distribution Channel outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Measles, Mumps, Rubella Vaccines Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Trends and Outlook
• 3.4. Market Dynamics
  • 3.4.1. Strengthened government immunization programs
  • 3.4.2. Resurgent outbreaks and rising disease burden
  • 3.4.3. Public awareness and education campaigns
• 3.5. Market Restraint Analysis
  • 3.5.1. Vaccine hesitancy and misinformation
• 3.6. Type Analysis Tools
  • 3.6.1. Porter's Five Forces Analysis
  • 3.6.2. PESTEL Analysis
• 3.7. Market Opportunity Analysis
• 3.8. Market Emerging Strategies

Chapter 4. Measles, Mumps, Rubella Vaccines Market: Type Estimates & Trend Analysis

• 4.1. Measles, Mumps, Rubella Vaccines Market: Type Movement Analysis
• 4.2. Measles, Mumps, Rubella Vaccines Market Estimates and Forecast, by Type
• 4.3. Monovalent
  • 4.3.1. Monovalent Market, 2018 - 2030 (USD Million)
• 4.4. Trivalent (combined MMR)
• 4.5. Tetravalent
  • 4.5.1. Trivalent (combined MMR) Market, 2018 - 2030 (USD Million)
• 4.6. Tetravalent
  • 4.6.1. Tetravalent Market, 2018 - 2030 (USD Million)

Chapter 5. Measles, Mumps, Rubella Vaccines Market: Targeted Population Estimates & Trend Analysis

• 5.1. Measles, Mumps, Rubella Vaccines Market: Targeted Population Movement Analysis
• 5.2. Measles, Mumps, Rubella Vaccines Market Estimates and Forecast, by Targeted Population
• 5.3. Infants and Children (9 months to 12)
• 5.4. Adults
  • 5.4.1. Infants and Children (9 months to 12) Market, 2018 - 2030 (USD Million)
• 5.5. Adults
  • 5.5.1. Adults Market, 2018 - 2030 (USD Million)

Chapter 6. Measles, Mumps, Rubella Vaccines Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Measles, Mumps, Rubella Vaccines Market: Distribution Channel Movement Analysis
• 6.2. Measles, Mumps, Rubella Vaccines Market Estimates and Forecast, by Distribution Channel
• 6.3. Hospitals and Healthcare Institutions
  • 6.3.1. Hospitals and Healthcare Institutions Market, 2018 - 2030 (USD Million)
• 6.4. Vaccine Centers and Public Health Clinics
  • 6.4.1. Vaccine Centers and Public Health Clinics Market, 2018 - 2030 (USD Million)
• 6.5. Pediatric and Private Healthcare Clinics
  • 6.5.1. Pediatric and Private Healthcare Clinics Market, 2018 - 2030 (USD Million)

Chapter 7. Measles, Mumps, Rubella Vaccines Market: Regional Estimates & Trend Analysis

• 7.1. Measles, Mumps, Rubella Vaccines Market Share By Region, 2024 & 2030
• 7.2. Regional Market Share Analysis, 2024 & 2030
• 7.3. Regional Market Dashboard
• 7.4. Global Regional Market Snapshot
• 7.5. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 7.6. North America
  • 7.6.1. North America Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • 7.6.2. U.S.
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. U.S. Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • 7.6.3. Canada
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Canada Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • 7.6.4. Mexico
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Mexico Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
• 7.7. Europe
  • 7.7.1. Europe Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • 7.7.2. UK
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. UK Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • 7.7.3. Germany
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Germany Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • 7.7.4. France
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Framework
    • 7.7.4.4. France Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • 7.7.5. Italy
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory Framework
    • 7.7.5.4. Italy Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • 7.7.6. Spain
    • 7.7.6.1. Key Country Dynamics
    • 7.7.6.2. Competitive Scenario
    • 7.7.6.3. Regulatory Framework
    • 7.7.6.4. Spain Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • 7.7.7. Denmark
    • 7.7.7.1. Key Country Dynamics
    • 7.7.7.2. Competitive Scenario
    • 7.7.7.3. Regulatory Framework
    • 7.7.7.4. Denmark Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • 7.7.8. Sweden
    • 7.7.8.1. Key Country Dynamics
    • 7.7.8.2. Competitive Scenario
    • 7.7.8.3. Regulatory Framework
    • 7.7.8.4. Sweden Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • 7.7.9. Norway
    • 7.7.9.1. Key Country Dynamics
    • 7.7.9.2. Competitive Scenario
    • 7.7.9.3. Regulatory Framework
    • 7.7.9.4. Norway Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
• 7.8. Asia Pacific
  • 7.8.1. Asia Pacific Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • 7.8.2. Japan
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Japan Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • 7.8.3. China
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. China Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • 7.8.4. India
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Competitive Scenario
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. India Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • 7.8.5. Australia
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Competitive Scenario
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Australia Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • 7.8.6. Thailand
    • 7.8.6.1. Key Country Dynamics
    • 7.8.6.2. Competitive Scenario
    • 7.8.6.3. Regulatory Framework
    • 7.8.6.4. Thailand Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • 7.8.7. South Korea
    • 7.8.7.1. Key Country Dynamics
    • 7.8.7.2. Competitive Scenario
    • 7.8.7.3. Regulatory Framework
    • 7.8.7.4. South Korea Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
• 7.9. Latin America
  • 7.9.1. Latin America Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • 7.9.2. Brazil
    • 7.9.2.1. Key Country Dynamics
    • 7.9.2.2. Competitive Scenario
    • 7.9.2.3. Regulatory Framework
    • 7.9.2.4. Brazil Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • 7.9.3. Argentina
    • 7.9.3.1. Key Country Dynamics
    • 7.9.3.2. Competitive Scenario
    • 7.9.3.3. Regulatory Framework
    • 7.9.3.4. Argentina Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
• 7.10. MEA
  • 7.10.1. MEA Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • 7.10.2. South Africa
    • 7.10.2.1. Key Country Dynamics
    • 7.10.2.2. Competitive Scenario
    • 7.10.2.3. Regulatory Framework
    • 7.10.2.4. South Africa Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • 7.10.3. Saudi Arabia
    • 7.10.3.1. Key Country Dynamics
    • 7.10.3.2. Competitive Scenario
    • 7.10.3.3. Regulatory Framework
    • 7.10.3.4. Saudi Arabia Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • 7.10.4. UAE
    • 7.10.4.1. Key Country Dynamics
    • 7.10.4.2. Competitive Scenario
    • 7.10.4.3. Regulatory Framework
    • 7.10.4.4. UAE Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)
  • 7.10.5. Kuwait
    • 7.10.5.1. Key Country Dynamics
    • 7.10.5.2. Competitive Scenario
    • 7.10.5.3. Regulatory Framework
    • 7.10.5.4. Kuwait Measles, Mumps, Rubella Vaccines Market, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company Categorization
• 8.3. Strategy Mapping
• 8.4. Company Market Share Analysis, 2024
• 8.5. Company Profiles
  • 8.5.1. Merck & Co., Inc.
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. GSK
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. Serum Institute of India Pvt. Ltd.
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Sanofi
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. Shanghai Institute of Biological Products
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Beijing Institute of Biological Products
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Biological E Ltd.
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. Sinovac
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives